A Randomized, Double-Blind, Active Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 (AEGR-733) and Ezetimibe vs. Monotherapy in Subjects With Moderate Hypercholesterolemia

Trial Profile

A Randomized, Double-Blind, Active Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 (AEGR-733) and Ezetimibe vs. Monotherapy in Subjects With Moderate Hypercholesterolemia

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs Lomitapide (Primary) ; Ezetimibe
  • Indications Hypercholesterolaemia; Lipid metabolism disorders
  • Focus Therapeutic Use
  • Sponsors Aegerion Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jun 2009 Final results presented at the American Diabetes Association's 69th Scientific Sessions (7 June) and the International Symposium on Atherosclerosis (15 Jun).
    • 08 Nov 2008 Results reported at the 81st Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top